These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38435128)

  • 1. Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor.
    Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101209. PubMed ID: 38435128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line.
    Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101264. PubMed ID: 38827249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
    Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
    Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of stable suspension producer cell lines for serum-free lentivirus production.
    Klimpel M; Terrao M; Bräuer M; Dersch H; Biserni M; Melo Do Nascimento L; Schwingal S; Vogel JE; Ferlemann C; Brandt T; Lal NI; Bridgeman K; Petzke A; McDwyer E; Lim JL; Oh S; Brumatti G; Garcia Minambres A; Otte E; Noll T; Pirzas V; Laux H
    Biotechnol J; 2024 May; 19(5):e2400090. PubMed ID: 38719592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines.
    Klimpel M; Terrao M; Ching N; Climenti V; Noll T; Pirzas V; Laux H
    Biotechnol Bioeng; 2023 Sep; 120(9):2622-2638. PubMed ID: 37148430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.
    Valkama AJ; Leinonen HM; Lipponen EM; Turkki V; Malinen J; Heikura T; Ylä-Herttuala S; Lesch HP
    Gene Ther; 2018 Jan; 25(1):39-46. PubMed ID: 29345252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.
    Fiol CR; Collignon ML; Welsh J; Rafiq QA
    Mol Ther Methods Clin Dev; 2023 Sep; 30():221-234. PubMed ID: 37528866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing.
    Tran MY; Kamen AA
    Front Bioeng Biotechnol; 2022; 10():887716. PubMed ID: 35774066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.
    Lee CL; Chou M; Dai B; Xiao L; Wang P
    Biotechnol Bioeng; 2012 Jun; 109(6):1551-60. PubMed ID: 22179950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor.
    Powers AD; Drury JE; Hoehamer CF; Lockey TD; Meagher MM
    Mol Ther Methods Clin Dev; 2020 Dec; 19():1-13. PubMed ID: 32995355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct.
    Chen YH; Pallant C; Sampson CJ; Boiti A; Johnson S; Brazauskas P; Hardwicke P; Marongiu M; Marinova VM; Carmo M; Sweeney NP; Richard A; Shillings A; Archibald P; Puschmann E; Mouzon B; Grose D; Mendez-Tavio M; Chen MX; Warr SRC; Senussi T; Carter PS; Baker S; Jung C; Brugman MH; Howe SJ; Vink CA
    Mol Ther Methods Clin Dev; 2020 Dec; 19():47-57. PubMed ID: 32995359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
    Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
    Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
    Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
    Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
    Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
    Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density.
    Shen CF; Tremblay S; Sabourin-Poirier C; Burney E; Broussau S; Manceur A; Rodenbrock A; Voyer R; Loignon M; Ansorge S; Gilbert R
    Bioprocess Biosyst Eng; 2022 Aug; 45(8):1267-1280. PubMed ID: 35758994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System.
    McCarron A; Donnelley M; McIntyre C; Parsons D
    Hum Gene Ther Methods; 2019 Jun; 30(3):93-101. PubMed ID: 31084376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.
    Tona RM; Shah R; Middaugh K; Steve J; Marques J; Roszell BR; Jung C
    Mol Ther Methods Clin Dev; 2023 Jun; 29():93-107. PubMed ID: 36994313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture.
    Broussau S; Jabbour N; Lachapelle G; Durocher Y; Tom R; Transfiguracion J; Gilbert R; Massie B
    Mol Ther; 2008 Mar; 16(3):500-7. PubMed ID: 18180776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture.
    Suleman S; Fawaz S; Roberts T; Ellison S; Bigger B; Themis M
    J Virol Methods; 2024 Apr; 325():114884. PubMed ID: 38218417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
    Wang X; Olszewska M; Qu J; Wasielewska T; Bartido S; Hermetet G; Sadelain M; Rivière I
    J Immunother; 2015 Apr; 38(3):127-35. PubMed ID: 25751502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.